In addition, the discrepancy in PD-L1 expression was also identified in subclones within the tumour immune microenvironment harbouring impaired antigen processing and presentation machinery in patients receiving immunotherapies, and has been associated with poor clinical outcomes in melanoma and other cancer types such as lung cancer and colorectal carcinoma [78,79,80]. This evidence concerns the gene CD274 and neoplasm.